Profile data is unavailable for this security.
About the company
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
- Revenue in CHF (TTM)337.79m
- Net income in CHF-31.65m
- Incorporated2021
- Employees1.37k
- LocationPolyPeptide Group AGNeuhofstrasse 24BAAR 6340SwitzerlandCHE
- Phone+41 435020580
- Websitehttps://www.polypeptide.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharming Group NV | 278.83m | 294.01k | 851.41m | 426.00 | 387.50 | 4.15 | 70.11 | 3.05 | 0.0034 | 0.0034 | 0.4817 | 0.3206 | 0.8057 | 0.5655 | 7.89 | 717,642.70 | 0.0156 | 2.22 | 0.0191 | 2.68 | 89.90 | 89.40 | 0.0193 | 3.88 | 2.39 | 3.14 | 0.331 | -- | 21.15 | 9.46 | -12.26 | -- | -49.98 | -- |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 177.78m | -37.05m | 852.22m | 2.35k | -- | 1.05 | -- | 4.79 | -0.3545 | -0.3545 | 1.70 | 7.75 | 0.1303 | 0.6358 | 0.4977 | 679,399.90 | -2.74 | 3.29 | -3.80 | 4.46 | 44.16 | 37.24 | -21.03 | 10.59 | 1.33 | -1.45 | 0.3114 | 24.43 | -13.90 | -3.87 | -7.30 | 1.41 | 1.13 | -7.12 |
| CStone Pharmaceuticals | 22.56m | -42.01m | 858.98m | 93.00 | -- | 22.63 | -- | 38.08 | -0.3273 | -0.3273 | 0.1768 | 0.2612 | 0.1487 | 1.38 | 1.68 | 1,696,892.00 | -27.69 | -39.13 | -54.45 | -60.19 | -12.18 | 66.69 | -186.23 | -170.86 | 1.20 | -29.83 | 0.554 | -- | -12.21 | -- | 75.16 | -- | -- | -- |
| DBV Technologies SA | 2.92m | -94.32m | 861.07m | 109.00 | -- | 6.46 | -- | 294.41 | -0.9532 | -0.9532 | 0.0296 | 0.5319 | 0.0295 | -- | 0.2091 | 29,152.22 | -95.23 | -53.19 | -135.74 | -65.71 | -- | 92.99 | -3,225.05 | -1,296.09 | -- | -172.41 | 0.082 | -- | -73.61 | -22.35 | -56.96 | -- | -16.00 | -- |
| SSY Group Ltd | 451.14m | 64.88m | 862.18m | 5.70k | 13.54 | 1.23 | 7.79 | 1.91 | 0.223 | 0.223 | 1.55 | 2.46 | 0.3616 | 2.27 | 2.11 | 751,065.60 | 5.27 | 9.41 | 6.34 | 12.43 | 42.68 | 56.47 | 14.58 | 17.65 | 2.40 | 14.91 | 0.346 | 42.91 | -10.67 | 4.49 | -19.53 | -1.36 | -8.36 | 9.73 |
| Cisen Pharmaceutical Co Ltd | 396.92m | 54.90m | 864.96m | 3.30k | 15.81 | 1.26 | -- | 2.18 | 1.08 | 1.08 | 7.84 | 13.59 | 0.472 | 2.10 | 5.34 | 1,079,074.00 | 6.58 | 6.51 | 8.12 | 8.07 | 53.70 | 55.92 | 13.94 | 10.84 | 3.48 | -- | 0.0069 | 37.16 | -10.77 | -0.6464 | -2.38 | -0.2215 | -0.3051 | 10.42 |
| Polypeptide Group AG | 337.79m | -31.65m | 865.46m | 1.37k | -- | 2.86 | -- | 2.56 | -0.9504 | -0.9504 | 10.10 | 9.15 | 0.5153 | 2.06 | 6.35 | 261,651.20 | -4.83 | 0.555 | -6.57 | 0.7099 | 11.63 | 19.25 | -9.37 | 1.05 | 0.8234 | -0.1909 | 0.2517 | 62.37 | 4.28 | 10.70 | 61.97 | -- | 34.57 | -- |
| BioGaia AB | 132.29m | 28.62m | 870.86m | 242.00 | 31.25 | 7.91 | 28.33 | 6.58 | 3.29 | 3.29 | 15.21 | 12.99 | 0.847 | -- | -- | 6,356,066.00 | 18.32 | 15.48 | 20.63 | 16.86 | 73.37 | 73.12 | 21.63 | 26.35 | -- | -- | -- | 133.18 | 8.11 | 15.54 | -5.30 | 13.11 | -25.87 | 24.01 |
| Xeris Biopharma Holdings Inc | 204.82m | -12.04m | 870.88m | 394.00 | -- | -- | -- | 4.25 | -0.1033 | -0.1033 | 1.67 | -0.0052 | 0.77 | 0.7301 | 5.61 | 675,474.60 | -4.52 | -31.61 | -6.46 | -42.28 | 84.56 | 79.76 | -5.88 | -77.77 | 1.35 | 0.3853 | 1.00 | -- | 23.89 | 136.89 | 11.92 | -- | -4.75 | -- |
| China Animal Husbandry Industry Co., Ltd | 699.69m | 23.89m | 872.48m | 4.30k | 36.52 | 1.37 | -- | 1.25 | 0.21 | 0.21 | 6.15 | 5.60 | 0.6863 | 5.30 | 4.19 | 1,461,064.00 | 2.32 | 5.25 | 3.37 | 7.48 | 15.59 | 22.15 | 3.38 | 7.31 | 1.62 | -- | 0.1625 | 31.16 | 11.30 | 7.79 | -82.41 | -22.24 | -0.0699 | -21.83 |
| Zhejiang Ausun Pharmaceutical Co Ltd | 83.67m | 20.59m | 887.93m | 1.22k | 42.83 | 3.40 | -- | 10.61 | 0.2241 | 0.2241 | 0.8963 | 2.83 | 0.2472 | 0.9248 | 3.00 | 616,180.10 | 6.08 | 8.91 | 7.77 | 12.10 | 51.51 | 53.44 | 24.61 | 27.68 | 2.17 | -- | 0.1383 | 27.35 | -2.63 | 20.90 | -18.55 | 29.68 | 17.53 | 43.79 |
| Neuren Pharmaceuticals Ltd | 124.45m | 81.13m | 889.13m | -- | 11.30 | 4.97 | 10.96 | 7.14 | 1.14 | 1.14 | 1.76 | 2.60 | 0.8175 | -- | 12.92 | -- | 53.29 | 49.68 | 54.95 | 56.56 | -- | -- | 65.19 | 58.60 | -- | 63.36 | 0.00 | 0.00 | -5.63 | 202.59 | -9.57 | -- | -3.58 | -- |
Data as of Feb 17 2026. Currency figures normalised to PolyPeptide Group AG's reporting currency: Swiss Franc CHF
19.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Premier Fund Managers Ltd.as of 31 Dec 2024 | 1.71m | 5.17% |
| Newtyn Management LLCas of 04 Jul 2024 | 993.57k | 3.00% |
| PRIMECAP Management Co.as of 31 Oct 2024 | 990.44k | 2.99% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 498.38k | 1.51% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Jan 2026 | 480.03k | 1.45% |
| UBS Asset Management Switzerland AGas of 03 Feb 2026 | 477.08k | 1.44% |
| Vontobel Asset Management AGas of 31 Jan 2026 | 393.67k | 1.19% |
| BlackRock Investment Management (UK) Ltd.as of 31 Dec 2025 | 380.55k | 1.15% |
| HBM Partners AG (Investment Management)as of 30 Jun 2025 | 308.00k | 0.93% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 Jan 2025 | 217.50k | 0.66% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
